- Home
- CURV vs TSHA Comparison
CURV vs TSHA Comparison
Compare CURV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- TSHA
- Stock Information
- Founded
- CURV 2001
- TSHA 2019
- Country
- CURV United States
- TSHA United States
- Employees
- CURV N/A
- TSHA N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CURV Consumer Discretionary
- TSHA Health Care
- Exchange
- CURV Nasdaq
- TSHA Nasdaq
- Market Cap
- CURV 402.0M
- TSHA 403.7M
- IPO Year
- CURV 2021
- TSHA 2020
- Fundamental
- Price
- CURV $3.92
- TSHA $2.18
- Analyst Decision
- CURV Hold
- TSHA Strong Buy
- Analyst Count
- CURV 5
- TSHA 8
- Target Price
- CURV $6.13
- TSHA $6.63
- AVG Volume (30 Days)
- CURV 359.3K
- TSHA 6.7M
- Earning Date
- CURV 12-05-2024
- TSHA 11-13-2024
- Dividend Yield
- CURV N/A
- TSHA N/A
- EPS Growth
- CURV N/A
- TSHA N/A
- EPS
- CURV 0.12
- TSHA N/A
- Revenue
- CURV $1,133,356,000.00
- TSHA $9,915,000.00
- Revenue This Year
- CURV $0.61
- TSHA N/A
- Revenue Next Year
- CURV $1.04
- TSHA N/A
- P/E Ratio
- CURV $32.46
- TSHA N/A
- Revenue Growth
- CURV N/A
- TSHA N/A
- 52 Week Low
- CURV $2.18
- TSHA $1.19
- 52 Week High
- CURV $9.14
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- CURV 49.23
- TSHA 56.47
- Support Level
- CURV $3.81
- TSHA $1.96
- Resistance Level
- CURV $4.17
- TSHA $2.34
- Average True Range (ATR)
- CURV 0.26
- TSHA 0.26
- MACD
- CURV 0.03
- TSHA 0.06
- Stochastic Oscillator
- CURV 56.44
- TSHA 68.75
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America targeting 27 to 42-year-old women. It is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of e-Commerce platform and stores.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.